Overview
RS Oncology is an innovative biotechnology company leading scientific discoveries and global collaborations to improve the lives of patients with the most aggressive cancers. The initial focus is to develop our novel therapy for pleural mesothelioma and other cancers with metastic disease to the lung. Our first-in-kind and first-in-human drug, RSO-021, is currently in Phase 2 of the MITOPE study to prove its efficacy in a multicenter clinical trial in the UK. For more information about our clinical trial visit clinicaltrials.gov with reference number NCT05278975
Company News
RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study
Feb 01, 2024
Posted by RS Oncology LLC